Try our beta test site
3 studies found for:    Hematologic Malignancies | IPI-145
Show Display Options
Rank Status Study
1 Enrolling by invitation A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)
Condition: Hematologic Malignancy
Intervention: Drug: Duvelisib
2 Terminated A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
Condition: Hematologic Malignancies
Intervention: Drug: IPI-145 (duvelisib)
3 Completed Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
Conditions: Lymphoma;   Chronic Lymphocytic Leukemia;   Non-Hodgkin Lymphoma;   T-cell Lymphoma
Interventions: Drug: IPI-145;   Drug: Rituximab;   Drug: Bendamustine

Study has passed its completion date and status has not been verified in more than two years.